Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials-Reference-Cited by-同舟云学术

Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials

Published:2005-07 Issue:5 Volume:20 Page:327-341
ISSN:0885-6222
Container-title:Human Psychopharmacology: Clinical and Experimental
language:en
Short-container-title:Hum. Psychopharmacol. Clin. Exp.

Author:

Hudson James I.,Wohlreich Madelaine M.,Kajdasz Daniel K.,Mallinckrodt Craig H.,Watkin John G.,Martynov Oleg V.

Publisher

Wiley

Subject

Pharmacology (medical),Psychiatry and Mental health,Clinical Neurology,Neurology

Reference46 articles.

1. American Psychiatric Association. 1994. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association: Washington, DC.

2. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability

3. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis

4. Unmet needs in the pharmacological management of depression

Cited by 106 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Duloxetine enhances PAX6 expression and suppresses innate immune responses in murine LPS-induced corneal inflammation;The Ocular Surface;2024-10

2. Hyponatremia with Antidepressant: A Rare Side Effect from Duloxetine in a Child with Acute Leukemia;Journal of Palliative Medicine;2022-12-01

3. Weight-centric treatment of depression and chronic pain;Obesity Pillars;2022-09

4. Parkinsonism induced by duloxetine in a patient with schizoaffective disorder: A case report;Psychiatry Research Case Reports;2022-06

5. Hyposalivation and Xerostomia and Burning Mouth Syndrome;Oral and Maxillofacial Surgery Clinics of North America;2022-02